Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,691 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 409 of 641 · 7,691 filings

  • RF Acquisition Corp. II (RFAI) FY2024 10-K risk factors
    86 risks

    This is a blank check company with no operating history or revenues, searching for an initial business combination. Risks are heavily concentrated on shareholder redemption features, potential conflicts of interest, trust account liabilities, and tax consequences.

    Filed Mar 25, 2025
  • Arcadia Biosciences (RKDA) FY2024 10-K risk factors
    22 risks

    Substantial going concern doubt and low cash resources dominate operations and financing discussions.

    Filed Mar 25, 2025
  • RUM Group (RUM) FY2024 10-K risk factors
    55 risks

    RUM Group Inc. operates in a high-growth environment with platform content and monetization heavily reliant on third-party integrations and advertising revenue.

    Filed Mar 25, 2025
  • Socket Mobile (SCKT) FY2024 10-K risk factors
    27 risks

    Socket Mobile depends heavily on third-party app providers to drive sales of its data capture products.

    Filed Mar 25, 2025
  • Smithfield Foods (SFD) FY2024 10-K risk factors
    55 risks

    Volatility in commodity prices for meat, livestock, and feed ingredients heavily impacts operations. Extensive environmental, food safety, and animal health regulations drive compliance costs. Controlling shareholder WH Group owns approximately 92.7 percent of common stock, limiting governance protections.

    Filed Mar 25, 2025
  • Semtech (SMTC) FY2025 10-K risk factors
    51 risks

    China sales represent 43% of net sales, creating heavy exposure to trade policies and economic shifts in the region.,Authorized distributors account for 72% of net sales and can terminate contracts with little or no notice.,Supplier capacity constraints and the lack of long-term customer purchase commitments create severe revenue and inventory volatility.

    Filed Mar 25, 2025
  • Sanara MedTech (SMTI) FY2024 10-K risk factors
    38 risks

    SMTI faces significant risks from ongoing financial losses, heavy reliance on non-patented CellerateRX Surgical, and strict debt covenants.

    Filed Mar 25, 2025
  • SurgePays (SURG) FY2024 10-K risk factors
    20 risks

    Dissolution of the federal Affordable Connectivity Program threatens over 70% of historical revenue, forcing a business model shift.

    Filed Mar 25, 2025
  • Tenax Therapeutics (TENX) FY2024 10-K risk factors
    46 risks

    Tenax Therapeutics relies heavily on the clinical and commercial success of levosimendan for PH-HFpEF and imatinib for PAH. The company has a history of net operating losses, totaling $19.5 million in 2024, and operates with a very small team of just four full-time employees. Manufacturing is outsourced entirely to third parties, including Orion for levosimendan supply.

    Filed Mar 25, 2025
  • TON Strategy (TONX) FY2024 10-K risk factors
    30 risks

    Recurring net losses of $10.3 million in 2024 raise going concern and capital adequacy risks. Heavy customer concentration with a single client generating 26% of revenue poses revenue volatility. Nasdaq listing compliance risks threaten common stock liquidity under ticker VERB.

    Filed Mar 25, 2025
  • Union Bankshares (UNB) FY2024 10-K risk factors
    41 risks

    Union Bankshares has no prior year risk section on file.

    Filed Mar 25, 2025
  • Willamette Valley Vineyards (WVVI) FY2024 10-K risk factors
    21 risks

    Wine production faces extreme weather, wildfire smoke, and agricultural diseases that threaten grape supply. Operations rely on lines of credit and key executives like James W. Bernau and John Ferry. Strict regulation by the TTB, OLCC, and foreign agencies governs labeling, distribution, and licensing.

    Filed Mar 25, 2025

Companies covered

4,011 companies

371 more under A